Preferred Label : dupilumab;
Obsolete resource : false;
MeSH note : targets the alpha subunit of interleukin-4 receptor;
CISMeF synonym : REGN668; SAR231893;
MeSH hyponym : SAR-231893; REGN-668;
Is substance : O;
UNII : 420K487FSG;
Origin ID : C582203;
UMLS CUI : C3660996;
ATC code(s)
- MeSH indexing information
- MeSH term(s) associated for indexing
- Record concept(s)
- See also inter- (CISMeF)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
https://www.has-sante.fr/jcms/p_3556159/fr/dupixent-dupilumab-bronchopneumopathie-chronique-obstructive-bpco
2025
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
injections, subcutaneous
evaluation of the transparency committee
dupilumab
pulmonary disease, chronic obstructive
---
https://www.has-sante.fr/jcms/p_3539126/fr/dupixent-dupilumab-biotherapies-par-voie-sous-cutanee-dans-les-maladies-inflammatoires-chroniques
2024
false
false
false
France
drug prescriptions
evaluation of the transparency committee
chronic disease
biological therapy
dupilumab
injections, subcutaneous
---
https://www.has-sante.fr/jcms/p_3500387/fr/dupixent-dupilumab-dermatite-atopique
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
dupilumab
injections, subcutaneous
adult
Adult atopic dermatitis (disorder)
evaluation of the transparency committee
dermatitis, atopic
dupilumab
---
https://www.has-sante.fr/jcms/p_3473151/fr/fiche-bum-dupixent-fasenra-nucala-tezspire-et-xolair-dans-le-traitement-de-l-asthme-severe
2024
false
false
false
France
dupilumab
benralizumab
mepolizumab
tezepelumab
other systemic drugs for obstructive airway diseases
adult
child
drug therapy, combination
Severe persistent asthma (disorder)
adolescent
Respiratory corticosteroid (substance)
adrenergic beta-2 receptor agonists
guidelines for drug use
Omalizumab
asthma
---
https://www.has-sante.fr/jcms/p_3465275/fr/dupixent-dupilumab-prurigo-nodulaire
2024
false
false
false
France
dupilumab
Prurigo nodularis (disorder)
adult
treatment outcome
insurance, health, reimbursement
evaluation of the transparency committee
dupilumab
prurigo
---
https://ansm.sante.fr/tableau-acces-derogatoire/dupixent
2024
false
false
false
France
French
summary of product characteristics
package leaflet
injections, subcutaneous
dupilumab
adult
Prurigo nodularis (disorder)
guidelines for drug use
prurigo
dupilumab
dermatitis, atopic
child
---
https://www.has-sante.fr/jcms/p_3433401/fr/dupixent-dupilumab-dermatite-atopique-severe-de-l-enfant-age-de-6-mois-a-5-ans
2023
false
false
false
France
infant
insurance, health, reimbursement
treatment outcome
dupilumab
Childhood atopic dermatitis (disorder)
injections, subcutaneous
receptors, interleukin
evaluation of the transparency committee
child
dermatitis, atopic
dupilumab
---
https://www.has-sante.fr/jcms/p_3427722/fr/dupixent-dupilumab-prurigo-nodulaire-pn
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
prurigo
Prurigo nodularis (disorder)
injections, subcutaneous
dupilumab
evaluation of the transparency committee
dupilumab
---
https://www.has-sante.fr/jcms/p_3168602/fr/dupixent-dupilumab
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
dermatitis, atopic
dupilumab
injections, subcutaneous
adolescent
evaluation of the transparency committee
dupilumab
---
https://www.has-sante.fr/jcms/p_3383104/fr/dupixent-dupilumab-dermatite-atopique-enfant-6-mois-5-ans
2022
false
false
false
France
infant
treatment outcome
insurance, health, reimbursement
guidelines for drug use
dupilumab
evaluation of the transparency committee
dupilumab
dermatitis, atopic
child
---
https://www.has-sante.fr/jcms/p_3368043/fr/dupixent-dupilumab-prurigo-nodulaire
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
Prurigo nodularis (disorder)
prurigo
dupilumab
injections, subcutaneous
dupilumab
adult
guidelines for drug use
evaluation of the transparency committee
---
https://www.has-sante.fr/jcms/p_3345836/fr/dupixent-dupilumab-asthme-severe-de-l-enfant-age-de-6-a-11-ans
2022
France
evaluation of the transparency committee
dupilumab
Child
child, nos
asthma
Child
Child
due to
asthma, nos
age, nos
severe
Asthma
Child
dupilumab
Dupixent
asthma
child
---
https://www.has-sante.fr/upload/docs/application/pdf/2021-09/dupixent_06072021_avis_economique.pdf
2021
France
health technology assessment
Child
dermatitis
atopic dermatitis, nos
Atopic dermatitis
dupilumab
dupilumab
Dupixent
Child
child, nos
child
Child
Child
dermatitis, atopic
---
https://www.has-sante.fr/jcms/p_3262655/fr/dupixent-dupilumab-dermatite-atopique-severe-enfant
2021
false
false
false
France
treatment outcome
insurance, health, reimbursement
injections, subcutaneous
dupilumab
child
dermatitis, atopic
evaluation of the transparency committee
dupilumab
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/jcms/p_3178278/fr/dupixent
2020
false
false
false
France
dupilumab
evaluation of the transparency committee
dupilumab
antibodies, monoclonal
---
https://www.has-sante.fr/jcms/p_3187477/fr/dupixent
2020
false
false
false
France
dupilumab
adolescent
insurance, health, reimbursement
treatment outcome
dermatitis, atopic
injections, subcutaneous
asthma
Nasal polyposis
evaluation of the transparency committee
dupilumab
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/jcms/p_3202975/fr/dupixent
2020
false
false
false
France
insurance, health, reimbursement
treatment outcome
glucocorticoids
drug therapy, combination
adult
nasal polyps
Nasal polyposis
injections, subcutaneous
evaluation of the transparency committee
dupilumab
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/jcms/p_3168602/fr/dupixent
2020
false
false
false
France
dupilumab
receptors, interleukin-4
receptors, interleukin-13
treatment outcome
insurance, health, reimbursement
dermatitis, atopic
adolescent
evaluation of the transparency committee
dupilumab
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/jcms/p_3135568/fr/dupixent
2019
false
false
false
France
French
evaluation of the transparency committee
insurance, health, reimbursement
treatment outcome
injections, subcutaneous
asthma
adult
adolescent
dupilumab
antibodies, monoclonal, humanized
---
https://www.has-sante.fr/portail/jcms/c_2865400/fr/dupixent
https://www.has-sante.fr/portail/jcms/c_2865400/fr/dupixent-dupilumab-medicament-de-la-dermatite-non-corticoide
2018
false
false
false
France
French
dermatitis, atopic
adult
injections, subcutaneous
self administration
treatment outcome
receptors, interleukin-13
receptors, interleukin-4
aged
IgG4
dupilumab
evaluation of the transparency committee
guidelines for drug use
antibodies, monoclonal, humanized
dupilumab
immunoglobulin G
---
https://www.ema.europa.eu/medicines/human/EPAR/Dupixent
2017
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
dermatitis, atopic
adult
injections, subcutaneous
Prefilled Syringe Dosage Form
self administration
treatment outcome
receptors, interleukin-13
receptors, interleukin-4
drug monitoring
product surveillance, postmarketing
aged
drug interactions
pregnancy
breast feeding
immunoglobulin G
IgG4
drug evaluation, preclinical
antibodies, monoclonal, humanized
dupilumab
antibodies, monoclonal, humanized
dupilumab
dupilumab
---
